Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Delayed xenograft rejection

F H Bach1, H Winkler, C Ferran

  • 1Sandoz Center for Immunobiology, Harvard Medical School, New England Deaconess Hospital, Boston, MA 02215, USA. fbach@nedhmail.nedh.harvard.edu

Immunology Today
|August 1, 1996
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Significant lethality following liver resection in A20 heterozygous knockout mice uncovers a key role for A20 in liver regeneration.

Cell death and differentiation·2015
Same author

The universal NF-kappaB inhibitor a20 protects from transplant vasculopathy by differentially affecting apoptosis in endothelial and smooth muscle cells.

Transplantation proceedings·2006
Same author

Epstein-Barr virus infection is associated with endothelial Bcl-2 expression in transplant liver allografts.

Transplantation·2002
Same author

Overexpression of A20 in endothelial cells of vascularized grafts creates a protective barrier against TNF- and FAS-mediated apoptosis.

Transplantation proceedings·2001
Same author

The BH4 domain of A1, an anti-apoptotic bcl family gene, is necessary and sufficient for its antiinflammatory function in endothelial cells.

Transplantation proceedings·2001
Same author

A20 and BCL proteins exert a broad and complementary cytoprotective effect in endothelial cells via blockade of NF-kappaB and NFAT.

Transplantation proceedings·2001
Same journal

Foreword.

Immunology today·2020
Same journal

The origin and significance of anti-DNA antibodies.

Immunology today·2014
Same journal

Mutations of class II MHC molecules.

Immunology today·2014
Same journal

Antigen processing at the molecular level.

Immunology today·2014
Same journal

Phenotypically and functionally distinct T-cell subsets in anti-tumor responses.

Immunology today·2014
Same journal

Are MHC class II-restricted cytotoxic T lymphocytes important?

Immunology today·2014
See all related articles

Vascularized xenografts face rapid rejection due to thrombosis and immune cell activation. Overcoming these barriers is key to achieving prolonged xenograft survival and advancing transplantation science.

Area of Science:

  • Transplantation immunology
  • Vascular biology
  • Immunology

Background:

  • Significant progress has been made in understanding xenograft rejection mechanisms.
  • Hyperacute rejection can be overcome by targeting complement or antibodies.
  • Vascularized xenografts still face rapid rejection, typically within days.

Purpose of the Study:

  • To discuss the critical barriers to prolonged xenograft survival.
  • To highlight the role of endothelial cell activation and thrombosis.
  • To examine the contribution of host immune cells like NK cells and monocytes.

Main Methods:

  • Review of current understanding of xenograft rejection.
  • Analysis of mechanisms beyond hyperacute rejection.
  • Discussion of endothelial activation, platelet aggregation, and thrombosis.

Related Experiment Videos

  • Examination of natural killer cell and monocyte activation.

    • Main Results:

    • Endothelial cell activation and thrombosis are significant barriers.
    • Host natural killer cell and monocyte activation contribute to rejection.
    • Current strategies effectively address hyperacute rejection but not subsequent rapid rejection.

    Conclusions:

    • Overcoming thrombosis and immune cell activation is crucial for prolonged xenograft survival.
    • Further research into these mechanisms is needed to advance xenotransplantation.
    • Targeting endothelial activation and host immune responses represents the next frontier in xenotransplantation.